Silk Road Medical Inc (NASDAQ:SILK) Expected to Announce Earnings of -$0.27 Per Share

Analysts expect Silk Road Medical Inc (NASDAQ:SILK) to post earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Silk Road Medical’s earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.26). The firm is expected to issue its next quarterly earnings report on Tuesday, February 4th.

According to Zacks, analysts expect that Silk Road Medical will report full year earnings of ($21.10) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.71) per share, with EPS estimates ranging from ($0.76) to ($0.62). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Silk Road Medical.

Silk Road Medical (NASDAQ:SILK) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.01. The company had revenue of $17.00 million during the quarter, compared to the consensus estimate of $15.93 million. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year.

Several brokerages recently issued reports on SILK. Zacks Investment Research raised shares of Silk Road Medical from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Saturday, November 2nd. Argus began coverage on shares of Silk Road Medical in a report on Tuesday, August 20th. They set a “buy” rating and a $52.00 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $43.50.

In related news, major shareholder Pincus & Co. Warburg sold 630,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $39.50, for a total transaction of $24,885,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Several institutional investors have recently modified their holdings of SILK. Bank of Montreal Can purchased a new position in shares of Silk Road Medical during the second quarter worth $28,000. Elkfork Partners LLC purchased a new position in shares of Silk Road Medical during the second quarter worth $30,000. Horan Securities Inc. purchased a new position in shares of Silk Road Medical during the third quarter worth $33,000. Meadow Creek Investment Management LLC purchased a new position in shares of Silk Road Medical during the second quarter worth $36,000. Finally, FNY Investment Advisers LLC purchased a new position in Silk Road Medical in the second quarter valued at $70,000. 70.53% of the stock is owned by hedge funds and other institutional investors.

Shares of Silk Road Medical stock traded down $0.72 during trading hours on Friday, reaching $34.88. The company had a trading volume of 282,400 shares, compared to its average volume of 277,238. The company has a debt-to-equity ratio of 0.53, a current ratio of 14.32 and a quick ratio of 13.38. The business has a fifty day simple moving average of $33.11 and a 200 day simple moving average of $40.02. Silk Road Medical has a one year low of $27.83 and a one year high of $51.50.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Recommended Story: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with's FREE daily email newsletter.